The India-based company is close to completing the Phase I clinical trial of NRC-AN-019 in India, and is planning to conduct further clinical trials in the US and other countries.
Orphan drug designation is granted by the FDA to those drugs that treat rare diseases affecting less than 200,000 patients in the US.
FDA grants special incentives to the companies involved in the development of these drugs, such as a seven year marketing exclusivity, specific tax credits and waiver of prescription drug user fees.